Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227006 | 0.87 | GCK (0.36) | GCKCHRM2CHRM1KMT2AMEN1 | |
| SCHEMBL13621273 | 0.83 | GCK (0.36) | GCKCHRM2CHRM1PTGS2 | |
| SCHEMBL2646180 | 0.80 | GCK (0.57) | GCKCHRM2CHRM1KMT2AMEN1 | |
| SCHEMBL2646260 | 0.80 | GCK (0.57) | GCKCHRM2CHRM1KMT2AMEN1 | |
| SCHEMBL1107300 | 0.79 | GCK (0.56) | GCKCHRM2CHRM1KMT2AEPHX1 | |
| SCHEMBL27969237 | 0.78 | METAP2 (0.42) | CHRM2CHRM1KMT2AMEN1EPHX1 | |
| SCHEMBL1865136 | 0.78 | GCK (0.58) | GCKKMT2AMEN1EPHX1 | |
| SCHEMBL1107388 | 0.78 | GCK (0.58) | GCKKMT2AMEN1EPHX1 | |
| SCHEMBL1865137 | 0.78 | GCK (0.58) | GCKKMT2AMEN1EPHX1 | |
| SCHEMBL21226951 | 0.77 | L3MBTL1 (0.47) | KMT2AMEN1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370393-B2 | Stereoretentive cross-coupling of boronic acids | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370393-B2 | Stereoretentive cross-coupling of boronic acids | NBAS, CNKSR1, REL | GCK 3167/4885CHRM2 660/4885CHRM1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.